Consistent with others,10, 11 our findings support systematic screening for Aspergillus infection markers in critically ill patients with COVID-19. Although oseltamivir-induced inhibition of the host neuraminidase activity has been suggested as a possible molecular mechanism leading to decreased anti-Aspergillus protective immunity in patients with influenza, the exact reasons for increased vulnerability of the patients with COVID-19 to Aspergillus remain to be identified as well as the contribution of Aspergillus to COVID-19-related lung inflammation.